Rhumbline Advisers Grows Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Rhumbline Advisers raised its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 13.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 103,233 shares of the company’s stock after acquiring an additional 12,315 shares during the quarter. Rhumbline Advisers owned about 0.15% of Nurix Therapeutics worth $1,945,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Amalgamated Bank raised its stake in shares of Nurix Therapeutics by 30.6% during the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after purchasing an additional 511 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after buying an additional 559 shares in the last quarter. Quarry LP lifted its holdings in shares of Nurix Therapeutics by 3,746.2% in the third quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after buying an additional 2,435 shares in the last quarter. International Assets Investment Management LLC boosted its position in shares of Nurix Therapeutics by 1,098.4% in the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after acquiring an additional 4,119 shares during the period. Finally, Quest Partners LLC boosted its position in shares of Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after acquiring an additional 1,312 shares during the period.

Nurix Therapeutics Stock Down 8.2 %

NASDAQ NRIX opened at $14.19 on Tuesday. The company has a 50-day simple moving average of $18.51 and a two-hundred day simple moving average of $21.78. Nurix Therapeutics, Inc. has a 12-month low of $11.90 and a 12-month high of $29.56. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -4.91 and a beta of 2.14.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. Equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NRIX has been the topic of a number of analyst reports. Royal Bank of Canada upped their target price on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Morgan Stanley increased their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research report on Monday, February 3rd. Stephens restated an “overweight” rating and set a $31.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Needham & Company LLC decreased their target price on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Finally, HC Wainwright lifted their price target on Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $31.81.

Insider Activity

In related news, CFO Houte Hans Van sold 5,825 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total transaction of $84,404.25. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at $488,660.76. This represents a 14.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the sale, the insider now directly owns 55,937 shares of the company’s stock, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 12,326 shares of company stock valued at $213,449. 7.20% of the stock is currently owned by company insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.